

Patent Information Initiative for Medicines

Pat-INFORMED

December 3, 2018

Thomas Bombelles

Head, NGO and Industry Relations

What is Pat-INFORMED?

- The **Patent Information Initiative for Medicines**, (Pat-INFORMED) is a search engine to help pharmaceutical procurement agencies determine the patent status of a medicine.
- It **facilitates access to and availability of pharmaceutical patent information** to inform procurement decisions.
- Pat-INFORMED is a partnership among WIPO, IFPMA and 20 global pharma companies.

Why create Pat-INFORMED?

- Greater transparency of patent information on medicines.
- “WIPO Development Agenda Goal 31:” ... Better access to publicly available patent information...
- UN Sustainable Development Goals:
 - Goal 3. Promote health and well-being
 - Goal 9. Foster innovation
 - Goal 17. Strengthen implementation through partnerships

Which therapeutic areas does Pat-INFORMED cover?

HIV/
AIDS

Cardiovascular
diseases

Diabetes

Hepatitis
C

Oncology

Respiratory
conditions



All products on the WHO EML that are not within these therapy areas

→ After the launch, the database will begin to be expanded to other therapeutic areas.

Who can use Pat-INFORMED?



- Pat-INFORMED is accessible to everybody, but it is specifically aimed at pharmaceutical procurement services and related specialists of:



- International bodies and donors
- National pharmaceutical services
- Ministries of health
- National patent offices



Search pharmaceutical patents by INN - Ex : erlotinib hydrochloride



Country ▼

[Display all INNs](#)

INN	Participant	Patents
Fluticasone Propionate, Salmeterol Xinafoate		AEROSOL CONTAINER FOR FORMULATIONS OF SALMETEROL XINAFOATE
Fosamprenavir Calcium		CALCIUM (3S) TETRAHYDRO-3-FURANYL(1S,2R)-3-[[[(4-AMINOPHENYL) SULFONYL] (ISOBUTYL) AMINO]-1-BENZYL-2- (PHOSPHONOXY) PROPYL]CARBAMATE
Dasatinib		FORMULATIONS OF A SRC/ABL INHIBITOR
Erlotinib Hydrochloride		STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF
Vemurafenib		COMPOUNDS AND METHODS FOR DEVELOPMENT OF RET MODULATORS
Lenvatinib Mesilate		QUINOLINE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION
Azilsartan Medoxomil, Chlortalidone		SOLID PHARMACEUTICAL COMPOSITION
Enzalutamide		Treatment Of Hyperproliferative Disorders With Diarylhydantoin Compounds
Efavirenz		CRYSTALLINE EFAVIRENZ
Umeclidinium Bromide, Vilanterol Trifenatate		PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
Fluticasone Furoate		COUNTER FOR USE WITH A MEDICAMENT DISPENSER
Abacavir Sulfate		CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS
		POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY



[Display all INNs](#)

INN	Participant	Patents
Sunitinib Malate		<p>CRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO) ETHYL]-5-[(5-FLUORO-2-OXO-3H-INDOLE-3-YLIDENE) METHYL]-2, 4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS PREPARATION AND COMPOSITIONS THEREOF</p> <p>PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS</p>



PAT-INFORMED

Patent Information Initiative for Medicines



Sunitinib Malate Country

[Display all INNs](#)

INN	Participant	Patents
Sunitinib Malate		CRYSTALS INCLUDING A MALIC ACID SALT OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-2-OXO-3H-INDOLE-3-YLIDENE) METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE, PROCESSES FOR ITS PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS

Participant:

Grant number	1255752
(Country not covered by PATENTSCOPE.)	
Jurisdiction	CN - China
Publication number	1439005
Publication date	2003/08/27 (15 years ago)
Filing date	2001/02/15 (18 years ago)
Grant date	2007/08/01 (11 years ago)
Grant number	ZL01807269.0
Open in PATENTSCOPE	
Jurisdiction	CY - Cyprus
Publication number	1255752

The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I); and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

[Information on the company's policy that may be related to the product](#)

DISCLAIMER: Pat-INFORMED is not intended as a replacement for a freedom-to-operate analysis, is not free of errors, and should not be relied upon as a comprehensive inventory of patent information. Pending applications are not listed, and in certain cases licensing arrangements may prevent Participants from listing patents. Use of Pat-INFORMED is subject to its [Term of Use and Disclaimers](#)

Jurisdiction	CD - Congo, The Democratic Republic of the
Filing date	2010/08/24 (8 years ago)
Grant date	2016/11/11 (2 years ago)
Grant number	4010/2010
(Country not covered by PATENTSCOPE.)	

Jurisdiction	CL - Chile
Filing date	2001/02/15 (18 years ago)
Grant date	2008/06/09 (10 years ago)
Grant number	43.486

Jurisdiction	CO - Colombia
Publication number	528
Publication date	2003/05/30 (15 years ago)
Filing date	2001/02/15 (18 years ago)
Grant date	2010/09/30 (8 years ago)
Grant number	29102

Jurisdiction	CH - Switzerland
Publication number	1255752
Publication date	2002/11/13 (16 years ago)
Filing date	2001/02/15 (18 years ago)
Grant date	2007/08/08 (11 years ago)
Grant number	1255752
(Country not covered by PATENTSCOPE.)	

Jurisdiction	CN - China
Publication number	1439005
Publication date	2003/08/27 (15 years ago)
Filing date	2001/02/15 (18 years ago)
Grant date	2007/08/01 (11 years ago)
Grant number	ZL01807269.0
Open in PATENTSCOPE	

Jurisdiction	CY - Cyprus
Publication number	1255752
Publication date	2002/11/13 (16 years ago)
Filing date	2001/02/15 (18 years ago)
Grant date	2007/08/08 (11 years ago)
Grant number	CY1108032

Thank you

For further information contact:

Thomas Bombelles

- +41 22 338 82 96
- thomas.bombelles@wipo.int



Guilherme Cintra

- +41 22 338 32 22
- g.cintra@ifpma.org

